Alpine Immune Sciences, Inc. Company Profile & Data: stocks, market cap, financials, digital and more

                        
Company
Alpine Immune Sciences, Inc.Headquarters: Seattle, 
                        WA, United States
                    
Employees: 85
CEO: Dr. Mitchell H. Gold M.D.

                                    NASDAQ: ALPN
                                
                                            +1.25%
                                            
Market Cap$1.03 Billion

                        USD as of Jan. 1, 2024
                    
                            Market Cap History

Alpine Immune Sciences, Inc. Categories

United States Healthcare Biotechnology
United States Healthcare United States Biotechnology

Alpine Immune Sciences, Inc. market capitalization over time

Evolution of Alpine Immune Sciences, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Alpine Immune Sciences, Inc.

Top Competitors by Market Capitalization

Industry: Biotechnology

Company	Market Cap (USD)
Novo Nordisk	$309.91 B
Vertex Pharmaceuticals Incorporated	$117.36 B
CSL Limited	$95.75 B
Regeneron Pharmaceuticals, Inc.	$59.14 B
Marinomed Biotech AG	$58.56 B

Sector:

Company	Market Cap (USD)
Lilly	$699.59 B
Johnson & Johnson	$374.29 B
AbbVie	$336.94 B
Novo Nordisk	$309.91 B
UnitedHealth Group	$279.90 B

Detailed Description

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

Financials

Last Financial Reports Date	Dec. 31, 2024
Revenue TTM	CHF2.9 M
EBITDA	CHF0
Gross Profit TTM	CHF2.9 M
Profit Margin	42.25%
Operating Margin	169.02%
Quarterly Revenue Growth	%